The proportion of patients with non-small cell lung cancer (NSCLC) harboring aberrations in driver oncogenes, such as EGFR, is 20–25 % in Europe and the United States, and approximately 50 % in Asia. This evidence concerns the gene EGFR and non-small cell lung carcinoma.